Drug Report History #257874
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v4-FR | Version v2-FR |
|---|---|---|
| Language | French | French |
| Date Updated | 2025-12-04 | 2025-12-04 |
| Drug Identification Number | 02438364 | 02438364 |
| Brand name | SYNAGIS | SYNAGIS |
| Common or Proper name | Nom commun ou nom propre | Nom commun ou nom propre |
| Company Name | ASTRAZENECA CANADA INC | ASTRAZENECA CANADA INC |
| Ingredients | PALIVIZUMAB | PALIVIZUMAB |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | Taille de l’emballage | Taille de l’emballage |
| ATC code | J06BD | J06BD |
| ATC description | ||
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | ||
| Actual discontinuation date | 2020-01-01 | 2020-01-01 |
| Remaining supply date | ||
| Discontinuation status | Discontinued | Discontinued |
| Discontinuation decision reversal | No | No |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | Commentaires de l’entreprise - EN (Updated) | |
| Health Canada comments |